VCAM1 (Protein | Antibody | cDNA Clone | ELISA Kit)

All VCAM1 reagents are produced in house and quality controlled, including 15 VCAM1 Antibody, 2 VCAM1 ELISA, 52 VCAM1 Gene, 1 VCAM1 IP Kit, 5 VCAM1 Lysate, 5 VCAM1 Protein, 3 VCAM1 qPCR. All VCAM1 reagents are ready to use.

VCAM1 Protein (5)

VCAM1 Antibody (15)

VCAM1 ELISA Kit & Match Antibody ELISA Pair Set ( 2 )

VCAM1 cDNA Clone (52)

NM_001078.2
NM_011693.3
NM_012889.1
XM_004812161.1

VCAM1 Lysate (5)

More Product Popular With Customers

VCAM1 Background

Vascular cell adhesion molecule 1 (VCAM-1), also known as CD16, is a cell surface sialoglycoprotein belonging to the immunoglobulin superfamily. Two forms of VCAM-1 with either six or seven extracellular Ig-like domains are generated by alternative splicing, with the longer form predominant. VCAM-1 is an endothelial ligand for very late antigen-4 (VLA-4) and α4ß7 integrin expressed on leukocytes, and thus mediates leukocyte-endothelial cell adhesion and signal transduction. VCAM-1 expression is induced on endothelial cells during inflammatory bowel disease, atherosclerosis, allograft rejection, infection, and asthmatic responses. During these responses, VCAM-1 forms a scaffold for leukocyte migration. VCAM-1 also activates signals within endothelial cells resulting in the opening of an "endothelial cell gate" through which leukocytes migrate. VCAM-1 has been identified as a potential anti-inflammatory therapeutic target, the hypothesis being that reduced expression of VCAM-1 will slow the development of atherosclerosis. In addition, VCAM-1-activated signals in endothelial cells are regulated by cytokines indicating that it is important to consider both endothelial cell adhesion molecule expression and function during inflammatory processes.Immune CheckpointImmunotherapyCancer ImmunotherapyTargeted Therapy

VCAM1 References

  • Cook-Mills JM. (2002) VCAM-1 signals during lymphocyte migration: role of reactive oxygen species. Mol Immunol. 39(9): 499-508.
  • Preiss DJ, et al. (2007) Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis? Int J Clin Pract. 61(4): 697-701.